M edulloblastoMa is a common malignant brain tumor that mainly arises during infancy and childhood. With current multimodality therapy, children with medulloblastoma in developed countries have good long-term survival, with 5-year overall survival (OS) reported at 65%-71%. 8 However, the survival rate is not so encouraging in developing countries, 16 and there is a lack of published data about Chinese children with medulloblastoma, especially about their treatment status and outcomes. In this study, we retrospectively analyzed the clinical features and survival data from 67 pediatric cases of medulloblastoma to investigate the underlying reasons for this disparity of outcome.
ated with Shanghai Jiaotong University School of Medicine, from January 2007 to June 2013. All of the children underwent tumor resection or biopsy, and in all cases, the diagnosis of medulloblastoma was made on the basis of pathological examination of tumor specimens in Xinhua Hospital and confirmed by Dr. Adekunle M. Adesina (Texas Children's Hospital, Houston), who reviewed the sections. Clinical data were collected from the Xinhua Hospital database. All patients were followed up by clinic appointment or telephone interviews. The last follow-up date was October 31, 2014. Data collection and entry were approved by the ethics committee of Xinhua Hospital. The collected data included age, sex, travel time from the patient's hometown to Xinhua Hospital, annual family income, residence, reason for abandoning treatment, extent of tumor resection, postoperative radiotherapy (RT), postoperative chemotherapy, and clinical outcomes. The patients' residence was classified as rural or urban depending on the recorded address. Travel time, annual family income, and reasons for treatment abandonment were reported by the patients' parents via clinic interview or follow-up investigation. We designed a questionnaire to collect data on the reasons for abandoning treatment; parents were asked to rank the reasons from most to least important (Table 1) .
Risk Stratification
Patients with medulloblastoma are generally categorized as being in standard-risk or high-risk groups as defined by the Children's Cancer Study Group. The standard-risk group is defined as patients who are older than 3 years at diagnosis, without metastatic disease (M0), and have a residual tumor volume less than 1.5 cm; other patients are considered to be in the high-risk group. 7 
Treatment Modalities and Definitions
Tumor operation followed by craniospinal RT and adjuvant chemotherapy is the typical treatment modality for medulloblastoma. 3 We assigned patients to one of 3 groups based on treatment. The Op group was defined as patients who had undergone gross-total resection (GTR) or subtotal resection (STR) but did not receive any adjuvant therapy. The Op+RT group comprised patients who received adjuvant RT after resection, and the Op+RT+Chemo group comprised patients who completed all Op, RT, and chemotherapy treatment. In most cases, microdissection was used to resect the primary tumors via a posterior fossa craniotomy. Standard RT practice involves the use of craniospinal irradiation (36 Gy, 20 fractions) with a boost to the posterior fossa/primary tumor bed (54 Gy, 10 fractions). For patients younger than 3 years of age, RT usually would be delayed until they were older than 3 years. The chemotherapy regimens included a routine combination of lomustine, cisplatin, and vincristine. Adjuvant temozolomide was used in a few cases. Treatment was considered to have been abandoned if a patient did not begin a specified treatment course or if the patient missed 4 or more successive weeks of treatment. 
Statistical Analysis
Statistical analysis was performed with the software IBM SPSS Statistics 18 (IBM Corp.). Survival rates were estimated by means of the Kaplan-Meier method. Overall survival (OS) was calculated as the time from diagnosis to death from any cause or the last follow-up. Progressionfree survival (PFS) was calculated as the time from diagnosis to any of the following: disease progression, tumor recurrence, occurrence of metastatic disease, and death from any cause. Cases in which treatment was abandoned were censored at the date of abandonment. The log-rank test was used for univariate analysis of prognostic variables. Variables with a p value < 0.05 in univariate analysis were entered into the multivariate Cox proportionalhazards regression model. Relationships between travel time from the patient's hometown to the hospital, annual family income, family residence, and treatment abandonment were evaluated by chi-square test. A p value < 0.05 was considered to indicate statistical significance. The last follow-up date was October 31, 2014.
results

Patient Characteristics
A total of 67 patients were in this cohort, including 17 infants or very young children (< 3 years of age) and 50 children between 3 and 16 years of age. The median age at diagnosis was 51.96 months (range 3.96-168.24 months). Forty-five patients (67%) were male, and 22 (33%) were female. The male/female ratio was approximately 2:1. The most common symptoms were those associated with intracranial hypertension, such as nausea or vomiting (69%), headache (29%), and cerebellar dysfunctional symptoms such as ataxia (45%) and diplopia (3%). The median prediagnostic interval (interval from symptom onset to confirmed diagnosis) was 1 month (range 4 hours to 2 years). Thirty-seven patients (55.2%) had transferred from one hospital to another more than twice. According to risk group classification, 26 patients (39%) were in the stan- dard-risk group, and 41 patients (61%) were in the highrisk group. The patients came from different provinces or regions across China. Thirty-eight (55%) came from poor rural areas, whereas 29 (43%) were from economically prosperous urban areas. Based on the survey, the median annual family income was $2910 (range $500-$7056). Approximately half of the patients' families (33 families) had an annual income higher than $3000, and half (34 families) had lower than that level. The average total cost of medulloblastoma treatment in Xinhua Hospital was about $19,926 (Fig. 1) . The median travel time (by train or bus) from the patient's hometown to Xinhua Hospital was 6 hours (range 1-16 hours).
Treatment Outcome
At the final follow-up date, 31 patients (46%) were alive, 30 (45%) had died, and 6 (9%) had been lost to follow-up. In 4 of the 6 cases in which patients were lost to follow-up, the phone numbers that we had from the patients' initial registration were either wrong or invalid; in the other 2 cases, the parents intentionally disconnected the follow-up calls. As for the treatment modalities, 22 patients had resective surgery (GTR or STR) without adjunctive treatment and made up the Op group; 9 patients were included in the Op+RT group; and 35 patients in the Op+RT+Chemo group completed all the recommended therapy procedures. In 1 case, the family refused any other treatment after the tumor was diagnosed by biopsy; this patient was not included in any of the 3 treatment groups. In 37 cases (55.2%), the patients had used Chinese medicine outside the specialist hospital.
Treatment was abandoned in 21 of 67 cases, resulting in an overall treatment abandonment rate of 31%. The major reasons for abandonment included misunderstandings about medulloblastoma and financial or transportation difficulties (Table 1) . In 1 case, the cause of treatment abandonment could not be determined.
Survival Analysis
The median follow-up time was 21 months (range 3-70 months). The estimated 3-year OS and 3-year PFS were 55.1% ± 6.4% and 45.6% ± 6.7%, respectively. Patients older than 3 years had higher 3-year OS than younger patients (63.1% ± 7.2% vs 31.37% ± 11.7%, p = 0.010) (Fig. 2A) .
The 3-year OS of the standard-risk group was much higher than that of the high-risk group (67.5% ± 7.8% vs 36.3% ± 9.6%, p = 0.009) (Fig. 2B) . Patients who received GTR had higher 3-year OS than those who had STR (60.0% ± 6.5% vs 0% ± 0%, p = 0.012). The 3-year OS was higher in the Op+RT+Chemo group than in the Op+RT group (87.8% ± 5.7% vs 59.3% ± 18.5%, p = 0.140) and in the Op group (87.8% ± 5.7% vs 0.00% ± 0.0%, p < 0.001). The 3-year OS was also higher in the OP+RT group than in the Op group (59.3% ± 18.5% vs 0.00% ± 0.0%, p < 0.001) (Fig.  2C) . Treatment abandonment greatly affected the 3-year OS (87.8% ± 5.7% for patients with complete treatment vs 25.2% ± 10.7% for those whose treatment was abandoned, p < 0.001) (Fig. 2D) . Patients with higher annual family income also had more favorable 3-year OS than patients with lower annual family income (66.5% ± 8.3% vs 42.1% ± 9.3%, p = 0.033) (Fig. 2E) . The 3-year OS of urban patients was higher than that of rural patients (71.8% ± 8.5% vs 41.0 ± 8.6%, p = 0.008) (Fig. 2F) . However, comparison of 3-year PFS between urban patients and rural patients (p = 0.110) and between patients with higher annual family income and patients with lower annual family income (p = 0.172) showed no statistically significant difference. The chi-square test showed that annual family income was closely related to the area of residence (p < 0.001). However, treatment abandonment was not correlated with travel time from the patient's hometown to the hospital (p = 0.051) (Fig. 3) , annual family income (p = 0.490) (Fig. 4) , or area of residence (p = 0.150) (Fig. 5) . Univariate analysis showed that older age (≥ 3 years) at diagnosis (p = 0.010), GTR (p = 0.012), standard-risk-group (p = 0.009), completion of both RT and chemotherapy in addition to surgery (p < 0.001), annual family income higher than $3000 (p = 0.033), and living in urban areas (p = 0.008) were favorable prognostic factors ( Table 2) . The above factors were all entered into a multivariate Cox proportional-hazards regression model, which revealed that the combination of postoperative RT and chemotherapy was an independent prognostic factor (p < 0.001). Since establishment of the Xinhua Multidisciplinary Collaboration Group for Pediatric Brain Tumors in our hospital in January 2011, the percentage of patients who completed postoperative RT and chemotherapy increased from 33% (10/30) to 68% (25/37) (p = 0.036). The treatment abandonment rate decreased from 43% (13/30) to 22% (8/37) (p = 0.069).
Discussion
Medulloblastoma is one of the most common primary CNS tumors in children, with an estimated incidence of 0.5 cases per 100,000 children. 3 For children, tumor resection followed by craniospinal irradiation and adjuvant chemotherapy is the typical treatment modality. 3, 6 Recent reports from Western countries suggest that, with multimodal therapy, 5-year OS approaches 85% for patients in the standard-risk group and 60% for those in the high-risk group. 5, 12 In our cohort of Chinese children, however, the 3-year OS rates of the standard-risk group and high-risk group were only 67.5% ± 7.8% and 36.3 ± 9.6%, respectively. Although the medical system in China has been renovated during the last 15 years, there is still a large gap between the outcome of medulloblastoma in Chinese children and children in developed countries. Many reasons are interrelated, such as misunderstandings about brain tumors, high treatment costs, parental socioeconomic status, shortage of specialists, and lack of a multidisciplinary team. The increasing social mobility and lack of standardized medical network make this issue more complicated for Chinese doctors.
In our analysis of clinical data, we found that treatment modality was the most significant prognostic factor. Abandonment was the major cause of treatment failure. In developing countries, treatment abandonment could affect up to 50%-60% of children with cancer. 2 The rate of abandonment does seem to be related to the type of cancer. For Wilms' tumor and Hodgkin's lymphoma, the treatment abandonment rate is usually 5%-10%. For acute leukemia, the rate varies from 16% to 50%. 2 However, we found very little information on treatment abandonment rates for children with brain tumors in developing countries. 14, 15 To our knowledge, our study is the first to report on abandonment of medulloblastoma treatment for children in China. The abandonment rate was 31% in this cohort. Because a large percentage of children with brain tumors are diagnosed and treated in nonspecialist children's hospitals, this scenario might be much worse across China.
The male/female ratio in this cohort was 2:1, which shows a stronger male preponderance than the previously reported ratio of 1.3:1. 3 The reports of the sixth Chinese population census released by National Bureau of Statistics cite a nationwide male/female ratio of 1.05:1 (http:// www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm). In some rural areas of China, people have a traditional preference for boys over girls. We suspected that the increased male preponderance in our study might be due to earlier abandonment of treatment after initial diagnosis in female children. Fig. 2 . Kaplan-Meier curves for OS in our patient cohort stratified by age, risk group, treatment modality, treatment abandonment, annual family income, and area of residence. a: The 3-year OS of patients 3 years of age or older was better than that of younger patients (63.1% ± 7.2% vs 31.37% ± 11.7%, p = 0.010). b: The 3-year OS of patients in the standard-risk group was much higher than that of those in the high-risk group (67.5% ± 7.8% vs 36.3% ± 9.6%, p = 0.009). c: The 3-year OS in the Op+RT+Chemo group was higher than that in the Op+RT group (87.8% ± 5.7% vs 59.3% ± 18.5%, p = 0.140) or Op group (87.8% ± 5.7% vs 0.00% ± 0.0%, p < 0.001). The 3-year OS in the Op+RT group was also higher than that in the Op group (59.3% ± 18.5% vs 0.00% ± 0.0%, p < 0.001). d: The 3-year OS of patients who completed the prescribed courses of therapy was better than that of those who did not (87.8% ± 5.7% vs 25.2% ± 10.7%, p < 0.001). e: Patients with higher annual family income also had more favorable 3-year OS than patients with lower annual family income (66.5% ± 8.3% vs. 42.1% ± 9.3%, p = 0.033). F: The 3-year OS was much higher for patients from urban areas than for those from rural areas (71.8% ± 8.5% vs. 41.0 ± 8.6%, p = 0.008).
The median prediagnostic interval in our cohort was 1 month (range 4 hours to 2 years), which was similar to the result of a large cohort in Canada that the median prediagnostic interval across all 126 medulloblastoma cases was 4 weeks (range 4-12 weeks). 13 It seemed that the Chinese parents did not lack awareness of early symptoms of a brain tumor, but before getting appropriate treatment, more than half of our patients (37/67, 55%) had to transfer from one hospital to another more than twice. This suggests that China has a serious shortage of pediatric brain tumor specialists.
The treatment protocols for medulloblastoma have not been standardized in China. Our center is one of the major specialist pediatric oncology centers in China, and we use a standardized treatment procedure, including microdissection, followed by RT and adjuvant chemotherapy. To avoid long-term sequelae, infants and children under the age of 3 years were treated only with chemotherapy after surgery. 1 The estimated 3-year OS for children who received complete courses of chemotherapy and RT, as well as undergoing surgery (the Op+RT+Chemo group), was 87.3% ± 5.4%, which is as good as the results reported by the UK National Registry of Childhood Tumors. 8 However, only 52% of the patients (35/67) completed scheduled treatment in our study, 31% (21/67) abandoned the planned therapy, and the other 17% (11/67) did not complete the therapy because of contraindications.
In addition to medical reasons, parental misconceptions regarding brain tumors and limited family resources seem to play an important role in abandoning treatment. 9, 14 We investigated the reasons for abandonment by using a questionnaire. The top 3 reasons (preference for alternative medicine, belief that brain tumors are incurable, and confusion regarding the treatment and prognosis of medulloblastoma) were all related to misunderstandings about medulloblastoma and its treatment. The wide use of Chinese medicine might explain the strong preference for alternative medicine. In our cohort, 37 patients (55.2%) had used Chinese medicine outside the specialist hospital. Because of the lack of standardization of Chinese medicine, we do not consider it a professional postoperative treatment. In addition, most parents tended to wish the surgery could cure medulloblastoma completely. If surgery could not remove all the symptoms, they might think postoperative therapy was also useless and unable to save the child. On the other hand, if the child appeared healthy after surgery, parents might think that the disease had been cured and postoperative therapy was unnecessary. Therefore, the correction of families' misconceptions about the treatment process and prognosis of brain tumor might prevent the abandonment of treatment in children with medulloblastoma. Financial difficulties and transportation to a major care center were also important reasons. We analyzed patients' annual family income and family residence areas. The average annual family income across China was 18,771 RMB ($2843) in 2013 (data obtained from the official website of NBS, http://data.stats.gov.cn/workspace/ index?m=hgnd). The median annual family income in our cohort was $2910. In light of the high average treatment costs ($19,926), it was reasonable to categorize those patients with an annual family income lower than $3000 as the poor group and the others as the wealthy group. Patients in the poor group had a poorer outcome than patients in the wealthy group (p = 0.033). The family financial status had a significant relationship with 3-year OS but not with 3-year PFS. This suggests that wealthier families had a stronger tendency to pursue medical treatment in the face of disease progression, and this might result in a transient prolongation of overall survival. Area of residence (rural vs urban) was also correlated with outcome (p = 0.008). Basically, people living in rural areas had lower income (p < 0.001), and they tended to travel long distances to reach a major hospital, which made it more difficult for patients to continue their long-term postoperative therapy. More than half of the patients (37/67, 55%) needed to travel more than 5 hours to get to Xinhua Hospital from their hometown. This suggests that the training of specialists in pediatric brain tumors should be an urgent issue for Chinese health care governors. In addition, parents who lived in rural areas with lower annual incomes often have a lower educational level and limited social resources, which could lead to lack of communication with doctors. As a result, the behavior of treatment abandonment represents an interaction between family financial difficulties and misunderstandings regarding brain tumor. Treatment abandonment is as much a socioeconomic issue as a medical one.
Because standard treatment strategies for CNS tumors have not yet been established, lack of a multidisciplinary team for treatment worsens the situation. 10 Initial consultation and multidisciplinary collaboration may have a positive effect on patients' compliance. 4, 11 Our multimodality team-consisting of specialists from pediatric neurosurgery, oncology, radiology, RT, and pathology-was established in 2011. The doctors from different departments get together to discuss the best remedy for each patient. We enhanced the initial consultation and provided parents with education of brain tumor's characteristics, treatment, prognosis, and daily care. Parents had close contact with all the pediatric brain tumor specialists during their hospitalization. With this collaboration, each patient's condition was discussed and treated cooperatively, and we subsequently experienced an increase in the treatment completion rate and a decrease in treatment abandonment.
Conclusions
With effective interventions to prevent treatment abandonment, the outcome of pediatric medulloblastoma could be greatly improved. On the basis of this study, we believe that the following 4 improvements could provide important benefits: 1) training more specialists in pediatric brain tumor to serve patients across our country; 2) having discussions with the children's parents about the benefits of postoperative therapy at diagnosis to provide them an accurate understanding of RT and chemotherapy; 3) providing close follow-up and making regular contact with patients to reduce the likelihood of treatment abandonment; and 4) establishing multidisciplinary teams for comprehensive treatment. These measures could enhance the compliance and completion rates for children with brain tumors in developing countries. Multicenter studies are still needed to evaluate the long-term outcome of pediatric medulloblastoma in China.
